FDA Commissioner nominee Scott Gottlieb has been a vocal critic of FDA bureaucracy and excessive data demands that in his view have slowed access to life-saving drugs and medical devices in the US. His expected confirmation as FDA head could offer a new glimmer of hope to sponsors seeking GRASE status for next-generation UV filters, a process that has all but ground to a halt, according to industry advocates.
Physician and conservative health policy analyst Scott Gottlieb has a history of challenging FDA bureaucracy that drags on access to innovative drugs and medical devices at the expense of American lives.
Now that he’s President Trump’s pick to lead the agency, stakeholders may be gearing up for a fresh assault on...
Green Pharmaceuticals’ SnoreStop Nasal Spray, previously marketed as “NasoSpray,” still is available even though agency officials on multiple occasions for a month recommended a recall after an April inspection found “gross microbial contamination” in one lot.
Global beauty giant is working to adapt its approach to the prestige market to meet escalating competition, increased points of sale, and more knowledgeable consumers with new shopping habits, CFO Tracey Travis said at the Barclays Global Consumer Staples Conference.
Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.
Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.
Week after publishing safety alert about OPMS Black Liquid Kratom “linked to serious adverse health effects, including death,” FDA announced market research “to understand and characterize emergent risk/safety and perceived benefits reportedly linked to kratom and psychedelics.” But it withdrew the study 10 days later.
Semi-annual regulatory agenda of non-binding target dates also sets December goal for an NPRM to recognize N-acetyl-L-cysteine as a lawful dietary ingredient. Like IND exemptions rule, item on NAC included for first time in FDA’s list.
